Alnylam Pharmaceuticals Profit Margin

The latest profit margin for ALNY is 16.82% as of June 2026. That compares with -13.4% in the prior-year period — up 225.5% year over year. That is above the Healthcare sector average of 14.34%. Investors often review this figure alongside Alnylam Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALNY's profit margin moved from -13.4% to 16.82% — a 225.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Alnylam Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, ALNY currently prints 16.82% for profit margin, while the sector average sits near 14.34%. That is roughly 17.2% above the sector mean. Large gaps often invite a closer look at Alnylam Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Alnylam Pharmaceuticals converts resources into returns. At 16.82%, ALNY may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -13.4% in the prior-year period — up 225.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ALNY's profit margin (16.82%), review year-over-year change from -13.4%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.